Recap: Arbutus Biopharma Q2 Earnings

Shares of Arbutus Biopharma ABUS fell 1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 45.65% over the past year to ($0.25), which missed the estimate of ($0.24).

Revenue of $1,514,000 up by 116.29% from the same period last year, which missed the estimate of $1,740,000.

Looking Ahead

Arbutus Biopharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 07, 2020

Time: 07:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/knwh3svj

Price Action

52-week high: $9.02

52-week low: $0.82

Price action over last quarter: Up 184.85%

Company Description

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.